The Mayo Clinic expert spoke about stem cell transplantation for patients with myeloma and the factors that affect the ability to collect stem cells.
The key to predicting when liquid biopsy would produce clinically actionable information is the ability to image the blood brain barrier and macrophages, according to researchers.
Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.
This study suggested that the National Comprehensive Cancer Network Distress Thermometer problem list does not easily identify concerns most associated with high distress and low quality of life in women with gynecologic cancers.
This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes.
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor.
The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer.
In this study, researchers found that 59% of the participants reported at least 1 barrier to endocrine therapy adherence, though over half reported that taking endocrine therapy was a joint decision between themselves and their doctor.
This study provides the first evidence of the urinary TERT promoter mutations to be used as simple and cost-effective non-invasive biomarkers for the early detection of bladder cancer.
In this study, higher intakes of dairy milk were correlated with greater risk of breast cancer, when adjusted for soy intake.
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.
A survey study documented slow progress in the advancement of palliative care programs and emphasized that access to timely palliative care continues to be a challenge for patients with cancer, especially those at non-National Cancer Institute cancer centers.
In this study, increased radiation dose was correlated with an increase in fatigue and dyspnea, as well as a decrease in physical activity, particularly in lung cancer or lymphoma.
Researchers found that poor infiltration of the tumor by immune cells, low activity from available T-cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to dampen responses to immunotherapy in this disease landscape.
LUNGevity Foundation released a Lung Cancer Scorecard to examine how effectively (or ineffectively) states are addressing lung cancer.